Anticancer Bioscience will seek strategic opportunities to partner and collaborate with pharma and biotech companies in the US and Europe to explore the versatility of its proprietary synthetic lethal platforms and compound library platforms and discover and develop therapeutics that target cancer.
We welcome discussions in the following areas:
- Platform collaborations
- Technology out-licensing
- Technology in-licensing
- Strategic collaborations
- Programme and asset licensing
- Combination therapy approaches
If you are interested in partnering with Anticancer Bioscience please contact us.